Valeritas Holdings announces a presentation at the 2nd Annual international Cannabinoid-Derived Pharmaceuticals Summit held in Boston, MA. The Summit focuses on scientific advances and commercial opportunities in the therapeutic uses of cannabinoids. It is a main industry platform for sharing data important to the advancement of safe and effective products. Valeritas is the maker of the h-Patch Drug Delivery Technology which offers simple and effective subcutaneous infusion.
They recently announced success with this method with two dosing regimens delivered using the h-Patch. The company believes that this study represents the first report of CBD delivered in this way in any preclinical model. The technology can aid with the delivery of typically injectable medicines. For example, their V-Go product uses the h-Patch technology to deliver insulin. More than 20 million V-Go insulin delivery devices have been sold in the US. Oral CBD solutions can be problematic, and the h-Patch avoids this. It maximizes the therapeutic result while minimizing the risks. This product could really open the door to reliable and consistent dosing.